Poster speculates that Abivax's down investor relations website could signal an imminent buyout announcement, and has placed a $10K bet on call options expiring the next day. Key risk: speculation is unsubstantiated and options expire in one day, making this an extremely high-risk, time-sensitive bet.

Abivax ($ABVX) is a European biotech lab with a patent on Obefazimod, a drug initially developed for HIV that shows superior efficacy (50%+ remission rates vs 15-35% for current treatments) in treating Ulcerative Colitis. The thesis is that Big Pharma desperately needs new drugs to replace $400B in annual sales facing patent cliffs by 2030, making acquisition or licensing of successful biotech compounds highly likely, positioning $ABVX as a potential 2-3x bagger. Key risks include clinical trial failures, regulatory setbacks, competition from established UC treatments, and potential dilution from financing needs.